General MedicationsINTRAMUSCULAR, SUBCUTANEOUSGeneric
BRAVELLE
UROFOLLITROPIN
Standard Dose
75 IU/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview BRAVELLE is listed in Drugs@FDA under application 021289 (BLA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient UROFOLLITROPIN Form and strength INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS - 75 IU/VIAL Sponsor FERRING Submission history Latest submission status date: 2015-10-27 00:00:00.
Structured Monograph
Clinical summary
Approval overview BRAVELLE is listed in Drugs@FDA under application 021289 (BLA). Review priority: STANDARD Marketing status: Discontinued Active ingredient UROFOLLITROPIN Form and strength INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS - 75 IU/VIAL Sponsor FERRING Submission history Latest submission status date: 2015-10-27 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.